Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

Learn more about CME

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

MoreVert
AddCircleOutlineFollow
ShareShare
AddCircleOutlineFollow
Follow
ShareShare
Share
1 Oct 2019

semaglutide 3 mg orally once daily improves glycemic control and semaglutide 7 and 14 mg orally once daily improve glycemic control and weight loss in adults with type 2 diabetes uncontrolled by diet and exercise alone (Diabetes Care 2019 Sep)

1 Oct 2019

semaglutide (Rybelsus) oral tablet FDA approved as adjunct to diet and exercise for treatment of type 2 diabetes in adults (FDA Press Release 2019 Sep 20)

27 Jun 2019

insulin degludec plus liraglutide may prolong time to need for treatment intensification compared to insulin glargine in insulin-naive adults with uncontrolled type 2 diabetes on oral antidiabetic drugs (Lancet Diabetes Endocrinol 2019 Jun 7 early online)

25 Jun 2019

semaglutide improves glycemic control and weight loss at 26 weeks in patients with uncontrolled type 2 diabetes and moderate renal impairment (Lancet Diabetes Endocrinol 2019 Jul)

25 Jun 2019

oral semaglutide improves glycemic control and weight loss at 26 weeks in patients with uncontrolled type 2 diabetes and moderate renal impairment (Lancet Diabetes Endocrinol 2019 Jul)

25 Jun 2019

oral semaglutide improves glycemic control and weight loss at 26 weeks in patients with uncontrolled type 2 diabetes and moderate renal impairment (Lancet Diabetes Endocrinol 2019 Jul)

25 Jun 2019

flexible-dose oral semaglutide may improve glycemic control and increase weight loss compared to fixed-dose sitagliptin in patients with inadequately controlled type 2 diabetes on 1-2 glucose-lowering medications (Lancet Diabetes Endocrinol 2019 Jun 6 early online)

25 Jun 2019

flexible-dose oral semaglutide may improve glycemic control and increase weight loss compared to fixed-dose sitagliptin in patients with inadequately controlled type 2 diabetes on 1-2 glucose-lowering medications (Lancet Diabetes Endocrinol 2019 Jun 6 early online)

25 Jun 2019

oral semaglutide and subcutaneous liraglutide have similar glycemic control at 26 weeks, but semaglutide induces greater weight loss up to 1 year in adults with uncontrolled type 2 diabetes on metformin (Lancet 2019 Jun 7 early online)

25 Jun 2019

oral semaglutide and subcutaneous liraglutide have similar glycemic control at 26 weeks, but semaglutide induces greater weight loss up to 1 year in adults with uncontrolled type 2 diabetes on metformin (Lancet 2019 Jun 7 early online)

25 Jun 2019

addition of dulaglutide to current glucose-lowering therapy may reduce risk of new macroalbuminuria in adults ≥ 50 years old with type 2 diabetes and previous cardiovascular disease or cardiovascular risk factors (Lancet 2019 Jun 7 early online)

25 Jun 2019

addition of dulaglutide to current glucose-lowering therapy may reduce risk of major adverse cardiovascular events in adults ≥ 50 years old with type 2 diabetes and previous cardiovascular disease or cardiovascular risk factors (Lancet 2019 Jun 7 early online)

18 Jun 2019

oral semaglutide and placebo may be associated with similar risk of major adverse cardiovascular events in patients ≥ 50 years old with type 2 diabetes at high cardiovascular risk (N Engl J Med 2019 Jun 11 early online)

18 Jun 2019

oral semaglutide and placebo may be associated with similar risk of major adverse cardiovascular events in patients ≥ 50 years old with type 2 diabetes at high cardiovascular risk (N Engl J Med 2019 Jun 11 early online)

21 Mar 2019

semaglutide once daily may improve glycemic control and reduce body weight compared to liraglutide once daily in patients with type 2 diabetes inadequately controlled with diet and exercise with or without metformin (Diabetes Care 2018 Sep)

21 Mar 2019

semaglutide once daily may improve glycemic control and reduce body weight compared to liraglutide once daily in patients with type 2 diabetes inadequately controlled with diet and exercise with or without metformin (Diabetes Care 2018 Sep)

16 Jul 2018

exenatide osmotic mini-pump reported to improve glycemic control in patients with HbA1c from 10% to 12% (Diabetes Care 2018 Mar)

19 Jun 2018

liraglutide may not be associated with increase in calcitonin concentrations or risk of developing C-cell malignancy in patients with type 2 diabetes and high cardiovascular risk (Diabetes Care 2018 Mar)

14 Jun 2018

insulin degludec/liraglutide and basal-bolus insulin associated with similar glycemic control, but insulin degludec/liraglutide may reduce hypoglycemic episodes and decrease weight in patients with inadequately controlled type 2 diabetes taking metformin (Diabetes Care 2018 May)

CheckCircle

top